Klinik für Innere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Saarland University Medical Center and Saarland University, Homburg, Germany.
Department of Cardiology, University Heart Center, University Hospital Basel, Basel, Switzerland.
Hypertens Res. 2024 Nov;47(11):3114-3125. doi: 10.1038/s41440-024-01900-7. Epub 2024 Sep 19.
Arterial hypertension remains the most important modifiable cardiovascular risk factor for morbidity and mortality worldwide. This review summarizes and discusses major clinical trials published in 2023 and early 2024 in hypertension research. These trials include new epidemiological data, studies investigating the impact of blood pressure cuff size on blood pressure measurements, benefits of salt substitutes, and novel antihypertensive treatment options, including pharmacotherapy and bariatric surgery in patients with obesity. This summary reviews the major clinical trials published in 2023 and early 2024. AHT arterial hypertension, BP blood pressure, HR hazard ratio, OBP office blood pressure, PRA plasma renin activity, SBP systolic blood pressure.
动脉高血压仍然是全球发病率和死亡率最重要的可改变心血管风险因素。这篇综述总结并讨论了 2023 年和 2024 年初发表的高血压研究中的主要临床试验。这些试验包括新的流行病学数据、研究血压袖带大小对血压测量影响的研究、盐替代品的益处，以及新型抗高血压治疗选择，包括肥胖患者的药物治疗和减肥手术。这篇综述总结了 2023 年和 2024 年初发表的主要临床试验。AHT 动脉高血压，BP 血压，HR 风险比，OBP 诊室血压，PRA 血浆肾素活性，SBP 收缩压。
